Qualigen Therapeutics President Amy Broidrick resigns; receives $360K annual severance for 12 months
AIxCrypto Holdings, Inc.
Amy Broidrick resigned as President, Chief Strategy & Operating Officer and director effective June 16, 2023; departure not related to any disagreement.
Separation agreement provides $16,636.79 for accrued salary/vacation and expense reimbursement.
Severance of $360,000 annual salary continued for 12 months post-separation, plus COBRA coverage for 12 months.
Broidrick has three months from separation to exercise vested stock options.
Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which became effective June 16, 2023
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Amy Broidrick resigned as President, Chief Strategy and Operating Officer at AIxCrypto Holdings, Inc..
Action
resigned
Role
President, Chief Strategy and Operating Officer
Exact text from the filing
Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which became effective June 16, 2023
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.